Identification of Cyclic Sulfonamides with an N-Arylacetamide Group as α-Glucosidase and α-Amylase Inhibitors: Biological Evaluation and Molecular Modeling
Open Access
- 17 January 2022
- journal article
- research article
- Published by MDPI AG in Pharmaceuticals
- Vol. 15 (1) , 106
Abstract
Diabetes mellitus (DM), a complicated metabolic disorder, is due to insensitivity to insulin function or reduction in insulin secretion, which results in postprandial hyperglycemia. α-Glucosidase inhibitors (AGIs) and α-amylase inhibitors (AAIs) block the function of digestive enzymes, which delays the carbohydrate hydrolysis process and ultimately helps to control the postprandial hyperglycemia. Diversified 2-(3-(3-methoxybenzoyl)-4-hydroxy-1,1-dioxido-2H-benzo[e][1,2]thiazin-2-yl)-N-arylacetamides were synthesized and evaluated for their in vitro inhibitory potential against α-glucosidase and α-amylase enzymes. The compounds with chloro, bromo and methyl substituents demonstrated good inhibition of α-glucosidase enzymes having IC50 values in the range of 25.88–46.25 μM, which are less than the standard drug, acarbose (IC50 = 58.8 μM). Similarly, some derivatives having chloro, bromo and nitro substituents were observed potent inhibitors of α-amylase enzyme, with IC50 values of 7.52 to 15.06 μM, lower than acarbose (IC50 = 17.0 μM). In addition, the most potent compound, N-(4-bromophenyl)-2-(4-hydroxy-3-(3-methoxybenzoyl)-1,1-dioxido-2H-benzo[e][1,2]thiazin-2-yl)acetamide (12i), was found to be a non-competitive and competitive inhibitor of α-glucosidase and α-amylase enzymes, respectively, during kinetic studies. The molecular docking studies provided the binding modes of active compounds and the molecular dynamics simulation studies of compound 12i in complex with α-amylase also showed that the compound is binding in a fashion similar to that predicted by molecular docking studies.Keywords
Funding Information
- Higher Education Commission, Pakistan (NRPU)
This publication has 92 references indexed in Scilit:
- Synthesis of novel pyrazolobenzothiazine 5,5-dioxide derivatives as potent anti-HIV-1 agentsMedicinal Chemistry Research, 2013
- Structure–Activity Relationship Studies of Sulfonylpiperazine Analogues as Novel Negative Allosteric Modulators of Human Neuronal Nicotinic ReceptorsJournal of Medicinal Chemistry, 2011
- Microwave assisted synthesis and structure–activity relationship of 4-hydroxy-N′-[1-phenylethylidene]-2H/2-methyl-1,2-benzothiazine-3-carbohydrazide 1,1-dioxides as anti-microbial agentsEuropean Journal of Medicinal Chemistry, 2011
- Docking and SAR studies of salacinol derivatives as α-glucosidase inhibitorsBioorganic & Medicinal Chemistry Letters, 2010
- (4-Hydroxy-1,1-dioxo-2H-1,2-benzothiazin-3-yl)(3-methoxyphenyl)methanoneActa Crystallographica Section E Crystallographic Communications, 2010
- Diabetes-Related Microvascular and Macrovascular Diseases in the Physical Therapy SettingPhysical Therapy, 2008
- A point‐charge force field for molecular mechanics simulations of proteins based on condensed‐phase quantum mechanical calculationsJournal of Computational Chemistry, 2003
- Comparison of degradation abilities of α- and β-amylases on raw starch granulesProcess Biochemistry, 2000
- Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favourable gastrointestinal toleranceInflammation Research, 1995
- Comparison of simple potential functions for simulating liquid waterThe Journal of Chemical Physics, 1983